IC
ITCI

Ikarian Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Ikarian Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-75,000
Closed -$2.54M – 303
2021
Q1 		$2.54M Sell
75,000
-25,000
-25% -$867K 0.09% 187
2020
Q4 		$3.18M Hold
100,000
– – 0.14% 123
2020
Q3 		$2.57M Buy
+100,000
New +$2.28M 0.19% 100
2020
Q1 		– Sell
-924,100
Closed -$31.7M – 182
2019
Q4 		$31.7M Buy
+924,100
New +$11.1M 5.14% 4

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's ITCI Position: Q4 2021 in Review

Ikarian Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2021, closing a stake of 211,670 shares — an estimated $7.89M sold.

Ikarian Capital first reported a position in ITCI in Q1 2020 and held it in 7 quarters. The position peaked at $11.2M in Q1 2021. 208 funds tracked by Wall St. Rank hold ITCI as of Q4 2021.

  • Ikarian Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2021 after selling out during the quarter.
  • Ikarian Capital sold 211,670 Intra-Cellular Therapies Inc. shares in Q4 2021, an estimated $7.89M.
  • Ikarian Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2020 and held it in 7 quarters.
  • Ikarian Capital's Intra-Cellular Therapies Inc. position peaked at $11.2M in Q1 2021.
  • 208 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2021.

Based on Ikarian Capital's 13F filing for Q4 2021, filed 14 Feb 2022.